
Opinion|Videos|November 13, 2025
FDA Approvals, Patient Selection, and SC Amivantamab
Panelists discuss how recent FDA approvals and SC amivantamab data support broader use of subcutaneous therapy in NSCLC.
Advertisement
Episodes in this series

Panelists discuss how recent FDA approvals for subcutaneous (SC) oncology agents are expanding therapeutic flexibility. They highlight approvals for SC versions of atezolizumab, nivolumab, and pembrolizumab, as well as clinical data from the PALOMA trials evaluating SC amivantamab. The discussion reviews findings demonstrating equivalent efficacy, safety, and pharmacokinetics to intravenous (IV) formulations. Panelists also address patient selection criteria, clinical considerations for integrating SC therapies with IV regimens, and how these innovations enhance workflow efficiency and patient experience.
Advertisement
Related to this article

In this Q&A, Konstantin Dmitrievich Penkov, MD, discusses delayed quality-of-life decline with cemiplimab plus chemotherapy in aNSCLC.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement
Trending on AJMC
1
Value-Based Pilot for Medicaid Members With Substance Use Disorder
2
Four Ways to Boost Awareness, Access for COVID-19 PEP
3
Health Equity & Access Weekly Roundup: November 20, 2026
4
Acne Treatment Adherence Ranges From 6% to 84% in Real-World Studies
5

